Saipei received US $28 million for respiratory test development
On August 13, 2021, the biomedical advanced research and Development Agency (BARDA) of the U.S. Department of health and human services recently announced that it had granted Cepheid a total of $28 million for product development related to sars-cov-2 detection. According to BARDA, the company’s xpert Xpress sars-cov-2 detection technology is developed in cooperation with BARDA and the U.S. Department of defense, which can detect viral nucleic acids in upper respiratory tract samples.
PBS biotech, a biotechnology company, completed a financing of US $10 million to provide production solutions for cell therapy
On August 16, 2021, it was learned that the biotechnology company PBS biotech and broadoak capital partners completed a round of private financing of US $10 million. This financing will enable the company to expand and industrialize the combination of its disposable bioreactor system and contract process development services. The company uses proprietary vertical wheeltm technology to achieve unique mixing characteristics and environmental conditions for cell therapy products.
Nuwa life completed tens of millions of yuan of angel round financing, which was exclusively invested by Jue capital
It was learned on August 20, 2021 that Guangzhou Nuwa Life Technology Co., Ltd., a new generation of assisted reproductive technology innovation company, successfully completed tens of millions of yuan of angel round financing on August 18, which was exclusively invested by Jue capital. Nuwa life is committed to becoming a global test tube baby advanced technology service provider. At present, Nuwa life has established a professional team with experience in drug development, production, quality control and clinical research to promote the industrialization of PIMS technology. Jue capital team said that the new generation of test tube baby screening technology PIMS of Nuwa life has a moat built by profound global exclusive patents, which can directly screen high-quality embryos, reduce the screening cost of test tube babies, improve the healthy birth rate and fertility quality, and has an extraordinary clinical demand. At the same time, “Nuwa life” is in line with the national policy of encouraging fertility and has high social value, so it is optimistic for a long time.
Pharmaceutical company Basilea announced an additional $4.3 million from BARDA to support the third phase development of ceftobiprole
On August 16, 2021, the biopharmaceutical company Basilea pharmaceutical Ltd. announced that it had been awarded an additional US $4.3 million non diluted fund by the biomedical advanced research and Development Agency (BARDA) to support the phase III plan of Basilea antibiotic ceftobiprole within the scope of the existing contract. Therefore, the total contract value increased to US $134.2 million. Basilea expects that the patient registration of eradicate study will be completed around the end of 2021, and the top line results of the study will be published in the first half of 2022 as planned.
Genomics company immnitas therapeutics completed round B financing of US $58 million, led by agent capital
On August 18, 2021, immunonitas therapeutics, a treatment company based on single cell genomics, announced that it had completed a round B financing of US $58 million. This round of financing was led by agent capital, and the participants included medical excellence capital (MEC), 120 capital, solasta ventures, mirae asset, Ono venture investment, the mark foundation for cancer research, NS investment Brightedge and Leukemia & Lymphoma Society therapy acceleration program ®（ LLS TAP）。 Existing investors Alexandria venture investments, evotec, leaves by Bayer, m ventures, Novartis venture fund (NVF) and Longwood fund follow. The funds obtained from the financing will be used to promote the company’s leading project imt-009 into the clinic to treat solid tumors and hematological malignancies.
Demata therapeutics, a drug research and development company, announced the completion of an initial public offering of $18 million
On August 17, 2021, dermata therapeutics, Inc., a clinical drug research and development company, announced that its previously announced initial public offering of 2571428 ordinary shares and accompanying warrants that can purchase up to 2571428 ordinary shares has been completed. Each ordinary share is sold together with a warrant to purchase one ordinary share at an exercise price of $7.00 per share and a combined issue price of $7.00. The total revenue is approximately $18 million before deducting underwriting discounts and issuance expenses. All ordinary shares and warrants are issued by the company. Ordinary shares and warrants began trading on the NASDAQ capital market on August 13, 2021, with stock codes of “drma” and “drmaw” respectively.
Jnana therapeutics, a biotechnology company, completed round B financing of US $50 million, led by RA capital management
On August 18, 2021, the biotechnology company Jnana therapeutics announced that it had completed a round B financing of US $50 million. This round of financing was led by RA capital management and followed by existing investors Polaris partners, versant ventures, Avalon ventures, abbvie ventures and Pfizer ventures. The financing funds will enable the company to promote the leading project for the treatment of phenylketonuria (PKU) to the clinical development stage, promote other project pipelines, and continue to invest in its innovative and proven rapid platform
Epiendo pharmaceuticals, a biopharmaceutical company, completed a round of financing of 20 million euros to promote the research and development of new drugs for the treatment of COPD
On August 18, 2021, epiendo pharmaceuticals, a biopharmaceutical company focusing on the use of new barrier enhancement methods to treat chronic inflammatory airway diseases, announced that it had completed a round of financing of 20 million euros, which was financed by flerie invest and I ð The UN venture fund led the investment, and the existing investor ABC ventures followed the investment. At the same time, the European Innovation Commission (EIC) fund also joined this round. The financing funds were used to promote the clinical development of the main compound ep395, which entered the phase I clinical trial in April and passed the phase IIa clinical trial.
Vigil neuroscience, a biotechnology company, completed round B financing of US $90 million, led by Vida ventures
On August 18, 2021, Vigil neuroscience, a biotechnology company for the treatment of neurodegenerative diseases, announced that it had completed a round B financing of US $90 million. This round of financing was led by Vida ventures, with existing investors atlas venture, northpond ventures and Hatteras venture partners and new investors surveyor capital, cormorant asset management, invus, orbited, Rock Springs capital Deep track capital, logos capital, pivotal bioventure partners and Lightstone ventures. The financing funds will further promote the company’s patented pipeline of microglia targeted drugs for the treatment of neurodegenerative diseases.
The pharmaceutical company Beckley psytech completed a round B financing of US $80 million, led by integrated
On August 16, 2021, it was learned that the pharmaceutical company Beckley psytech had completed a round B financing of US $80 million. This round of financing was led by integrated, followed by prime movers labs, adage capital management, Palo Santo, Delphi VC, leafy tunnel, Negev capital and existing investors bicycle day ventures. The company intends to use these funds to complete the ongoing phase 1b trial of low-dose psychedelic drugs on patients with sunha, a rare and debilitating headache.
Ultima, a supplier of sugar free electrolyte products, was invested by the customized capital solution provider, finance group and private equity firm WM partners
On August 17, 2021, Ultima health products, a supplier of sugar free electrolyte products, announced on August 3 that it had obtained investments from the customized capital solution provider finance group and the private equity investment company WM partners. The specific financial terms were not disclosed. The finance group and WM partners will jointly make subsequent debt and equity investments in Ultima.
Marijuana retailer medmen announced a $100 million equity investment led by serruya private equity
On August 17, 2021, marijuana retailer medmen Enterprises Inc. announced a US $100 million equity investment led by serruya private equity. The US $100 million income from private placement will enable medmen to expand its business in major markets such as California, Florida, Illinois and Massachusetts, and find and accelerate further growth opportunities throughout the United States.
3.Gene therapy and cell therapy
Biotechnology company taysha gene therapies announced a US $100 million undiluted term loan facility
On August 16, 2021, taysha gene therapies, a patient-centered gene therapy company, announced that it had reached a loan and guarantee agreement with Silicon Valley Bank (SVB), providing taysha with a non diluted term loan financing of up to US $100 million. At the end of the financing, $40 million was available, of which $30 million had been withdrawn by taysha. The company can choose to withdraw the remaining funds under certain conditions. The funds will further promote a strong development pipeline and achieve key milestones in the next few years.
Pharmacyte biotech, a biotechnology company, announced a registered direct offering of US $70 million at market price according to NASDAQ rules
On 2021 February 19, Biotech Corp PharmaCyte Biotech, Inc., which developed cancer and diabetes cell therapy, announced that it had reached a final agreement with institutional investors. Under the NASDAQ rules, it registered directly issued at the effective purchase price of $5 per share, and purchased and sold 14000000 common stocks with a total return of $70 million. The company also agreed to issue unregistered warrants to investors to purchase a total of 7 million ordinary shares. The offering is expected to be completed before and after August 23, 2021, but it must meet the normal transaction conditions.
Synchron, a minimally invasive neural interface technology company, completed a round B financing of US $40 million to accelerate clinical trials
It was learned on August 16, 2021 that synchron, a minimally invasive neural interface technology company, has completed a round B financing of US $40 million. This round of financing is led by Khosla ventures. Other investors include forepont capital partners, ID8 investments, Shanda group, general advance, subversive capital, re.mind capital, as well as personal arani Bose and Thomas rearon. Existing investors include neurotechnology investors, Metis innovative and the University of Melbourne. The funds obtained from the financing will be used to carry out key clinical research on the company’s stentrode technology in the United States.
Agilis robotics, a surgical robot company, obtained an angel round financing of RMB 10 million
It was learned on August 16, 2021 that agilis robotics, a surgical robot company, received an angel round financing of RMB 10 million, which was not disclosed by the investor. Agilis robotics is a surgical robot company incubated by the University of Hong Kong. Its prototype has been developed and can be used to assist surgeons in examinations or operations that may involve endoscopic assistance or laparoscopic assistance, such as the digestive tract system, large intestine bladder system, etc
Brainq, a medical equipment company, completed a $40 million financing to improve the rehabilitation of stroke patients
It was learned on August 16, 2021 that brainq, a medical equipment company, has completed a financing of US $40 million. The company’s goal is to improve the rehabilitation of stroke patients, promote self-healing by stimulating the damaged parts of the brain, and show sufficient improvement in the research, so as to ensure the breakthrough equipment certification of the US Food and Drug Administration (FDA).